Latest News - AstraZeneca
Top Corporates Hub
AstraZeneca
BNY Mellon International Equity Fund Q1 2025 Commentary
26.05.2025 11:48
BNY Mellon International Equity Fund outperformed its benchmark index, the MSCI EAFE (âthe indexâ), during the first quarter of 2025.
Why Investors Should Watch Teva Despite Regional Risks
23.05.2025 12:52
Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
23.05.2025 09:37
The collaboration aims to integrate the algorithms into routine eye examinations, facilitating diagnosis.
BlackRock International Fund Q1 2025 Commentary
16.05.2025 01:15
BlackRock International Fund posted returns of 1.08% (Institutional shares) and 1.00% (Investor A shares, without sales charge) for the first quarter of 2025.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
15.05.2025 13:40
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Vanguard FTSE All-World ex-US Index Fund ETF Is Very Well Positioned
15.05.2025 08:22
VEU is a top low-cost ETF for global diversification beyond U.S. stocks and the U.S. dollar. Click here to see why the Fund is a Buy.
Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
12.05.2025 11:33
Drugmakers' shares fell globally after President Trump said he would sign an executive order to lower the cost of prescription drugs. Shares of Japan's Daiichi Sankyo, which gets about a third of revenue from the U.S., dropped around 8%. Other Japanese drug stocks also fell.
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
12.05.2025 11:15
The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.
Invesco Oppenheimer International Growth Fund Q1 2025 Commentary
11.05.2025 01:38
During the quarter, apparent uncertainty about US industrial, tax and trade policy appeared to dampen equity market performance, particularly in the US. Read more here.
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
09.05.2025 11:00
WILMINGTON, Del., May 09, 2025--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.
The Top 40 UK Dividend Stocks For 2025 (Spring/Summer Edition)
09.05.2025 09:30
It has been ten months since I last updated the UK top 40 dividend stocks list, and much has happened since then.Trump has been doing his best to shake up...
Invesco International Diversified Fund Q1 2025 Commentary
09.05.2025 09:10
Invesco International Diversified Fund offers investors broad-based exposure to non-US equities by combining 4 portfolios that varied individual mandates regarding region & company size.